Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.68 |
| ▸ | GSPT1 | P15170 | 10/20 | 0.68 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.68 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.68 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31097010 | 1.00 | CRBN (0.68) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL17495152 | 0.84 | CRBN (0.69) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL30313225 | 0.82 | CRBN (0.68) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL29360673 | 0.81 | CRBN (1.00) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL61575 | 0.81 | CRBN (1.00) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL31305221 | 0.81 | CRBN (0.70) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL30865843 | 0.81 | CRBN (0.88) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL29225899 | 0.81 | CRBN (0.88) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL29225988 | 0.80 | CRBN (0.79) | CRBNGSPT1DDB1IKZF3CSNK1A1 | |
| SCHEMBL30865832 | 0.80 | CRBN (0.79) | CRBNGSPT1DDB1IKZF3CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024192146-A2 | COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS | SOUTHERN RESEARCH INSTITUTE (US) | 2024-09-19 | — | — | WO | disclosed |